Destiny-Breast06 Results Offer New Hope for Patients With HR

Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low metastatic breast cancer who had prior endocrine therapy.

Related Keywords

United States , Texas , American , Sebastian Kaulitzki , Susan Galbraith , Caffreym Trastuzumab , Debra Patt , Daiichi Sankyo , American Society Of Clinical Oncology , Us Food Drug Administration , Astrazeneca , Image Credit , American Society , Clinical Oncology , Texas Oncology , American Journal ,